FDA Fast-Tracks Decision on Promising Alzheimer’s Drug

Published on July 6, 2022

The FDA is moving at lightning speed to review Eisai Co Ltd’s and Biogen Inc’s potential breakthrough drug for Alzheimer’s. Dubbed lecanemab, this antibody therapy could be a game-changer, much like its predecessor Aduhelm. The FDA has announced that a decision will be made on January 6, 2023, providing hope for those suffering from Alzheimer’s and their loved ones. This accelerated review shows the urgent need for effective treatments in the fight against this devastating disease. If approved, lecanemab could revolutionize our approach to treating Alzheimer’s by targeting the underlying causes rather than just managing symptoms. With this exciting news, it’s important to delve into the research behind lecanemab and comprehend the science behind the potential breakthrough. Stay tuned for updates as we eagerly await the FDA decision!

The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd’s and Biogen Inc’s experimental Alzheimer’s drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday. Lecanemab, like the partners’ previous drug Aduhelm, is an antibody…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>